Cluster 1 aims at the detection of biomarkers that are characteristic for inflammatory diseases. The rationale behind this is that airway infections are the most prevalent class of infections in the Netherlands. Faster and more specific and more sensitive detection will assist adequate and early diagnosis of inflammatory diseases, which will greatly benefit the patient and reduce overall impact and costs of these diseases. The R&D programme will allow the electrical detection of individual biomarker molecules, based on the specific biomarker-receptor/antibody interaction.
Cluster 2 aims at the development of microsystems-based lab-on-a-chip systems for the improved (more sensitive and faster) detection of microbial pathogens. lt will focus on pathogens present in sputum, breath, serum and urine from patients with pulmonary diseases, such as tuberculosis and pneumonia. With the devices under development patients can be screened for pathogens in a direct way, providing results within an hour, while this currently takes up to many days.
Back to theme 3: Nanomedicine